Odyssey Therapeutics, Inc. (ODTX) shareholders
Close on Nov 17, 2026Market cap $930.89MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (13.00%) | 6,239,237 | 13.00% | 13G (passive) amendment | Sep 30, 2026 |
| SR One Capital Management, LLC Joint filing with Simeon George (8.00%) | 3,794,883 | 8.00% | 13D (active) | May 11, 2026 |
| Tpg Gp A, LLC Joint filing with James G. Coulter (7.80%), Jon Winkelried (7.80%) | 3,690,146 | 7.80% | 13D (active) | May 11, 2026 |
| Jeito II S.L.P. Joint filing with Jeito Capital SAS (7.80%), Rafaele Tordjman (7.80%) and 1 more | 3,690,145 | 7.80% | 13D (active) | May 8, 2026 |
| Lightspeed General Partner XV-B (Ignite), L.P. Joint filing with Lightspeed Venture Partners XV-B (Ignite), L.P. (7.60%), Lightspeed Ultimate General Partner XV-B (Ignite), L.L.C. (7.60%) | 3,608,443 | 7.60% | 13G (passive) | May 11, 2026 |
| Nan Li Joint filing with Dimension Management, L.P. (7.10%), Dimension Capital II, L.P. (7.10%) and 4 more | 3,333,516 | 7.10% | 13D (active) | May 8, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ODTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 5,179,262 | 10.78% | $96.90M | New | 0.00% |
| Sr One Capital Management, LP | 3,794,883 | 7.90% | $71.00M | New | 6.83% |
| Tpg Gp A, LLC | 3,690,146 | 7.68% | $69.04M | New | 1.38% |
| Lightspeed Management Company, L.L.C. | 3,608,443 | 7.51% | $67.51M | New | 2.81% |
| Orbimed Advisors LLC | 3,001,198 | 6.24% | $56.15M | New | 1.04% |
| Sanofi | 1,991,918 | 4.14% | $37.27M | New | 6.98% |
| Deerfield Management Company, L.P. (Series C) | 1,046,139 | 2.18% | $19.57M | New | 0.20% |
| Sands Capital Ventures, LLC | 875,000 | 1.82% | $16.37M | New | 2.67% |
| Hhlr Advisors, Ltd. | 831,656 | 1.73% | $15.56M | New | 1.87% |
| General Catalyst Group Management, LLC | 810,272 | 1.69% | $15.16M | New | 8.04% |
| Affinity Asset Advisors, LLC | 766,346 | 1.59% | $14.34M | New | 0.65% |
| Adage Capital Partners Gp, L.L.C. | 725,000 | 1.51% | $13.56M | New | 0.02% |
| Vanguard Capital Management LLC | 720,440 | 1.50% | $13.48M | New | 0.00% |
| Foresite Capital Management V, LLC | 713,105 | 1.48% | $13.34M | New | 3.68% |
| Vivo Capital, LLC | 575,000 | 1.20% | $10.76M | New | 0.98% |
| EcoR1 Capital, LLC | 555,555 | 1.16% | $10.39M | New | 0.51% |
| Logos Global Management LP | 521,736 | 1.09% | $9.76M | New | 0.42% |
| Marshall Wace, Llp | 492,697 | 1.03% | $9.22M | New | 0.01% |
| Price T Rowe Associates Inc /Md/ | 471,987 | 0.98% | $8.83M | New | 0.00% |
| Catalio Capital Management, LP | 457,839 | 0.95% | $8.57M | New | 1.61% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 58 | 35M | 72.4% | 58 / 0 | 0 / 0 | 35M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ODTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 595,900 | 1.24% | $10.14M | 0.01% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 531,096 | 1.11% | $9.94M | 0.00% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 339,500 | 0.71% | $5.77M | 0.11% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 182,547 | 0.38% | $3.42M | 0.03% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 179,659 | 0.37% | $3.36M | 0.00% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 164,696 | 0.34% | $2.80M | 0.01% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 147,400 | 0.31% | $2.51M | 0.01% | May 31, 2026 |
| Franklin Biotechnology Discovery Fund | 99,826 | 0.21% | $1.89M | 0.16% | Jul 31, 2026 |
| Schwab Total Stock Market Index Fund | 15,000 | 0.03% | $283.95K | 0.00% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 11,883 | 0.02% | $202.13K | 0.00% | May 31, 2026 |
| T. Rowe Price Health Sciences Portfolio | 11,276 | 0.02% | $210.97K | 0.03% | Jun 30, 2026 |
| Health Sciences Trust | 7,899 | 0.02% | $147.79K | 0.06% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 6,575 | 0.01% | $123.02K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 6,442 | 0.01% | $120.53K | 0.00% | Jun 30, 2026 |
| EQ/T.Rowe Price Health Sciences Portfolio | 5,571 | 0.01% | $104.23K | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Gary D. Glick | See Remarks, Director | 415,973 | 0.87% | May 11, 2026 |
| Jason Haas | Chief Financial Officer | 62,908 | 0.13% | May 11, 2026 |
| Natalie Dales | See Remarks | 36,880 | 0.08% | May 11, 2026 |
| Anthony W. Opipari | See Remarks | 7,506 | 0.02% | May 11, 2026 |
| Collin M. Todd | See Remarks | – | – | May 11, 2026 |
| Jolie Siegel | See Remarks | – | – | May 7, 2026 |
| Dimension Capital II, L.P. | Director | 512,862 | 1.07% | May 12, 2026 |
| Ian F. Smith | Director | 246,100 | 0.51% | May 11, 2026 |
| Timothy P. Walbert | Director | – | – | May 11, 2026 |
| Jeffrey M. Leiden | Director | 330,540 | 0.69% | May 11, 2026 |
| Nan (LN) Li | Director | 3,333,516 | 6.94% | May 11, 2026 |
| Ourania Tatsis | Director | – | – | May 11, 2026 |
| Valerie Odegard | Director | – | – | May 11, 2026 |
| Shelley Chu | Director | 11,111 | 0.02% | May 11, 2026 |
| Aranicki Ksenija Pavletic | Director | – | – | May 7, 2026 |
| Paulina Hill | Director | – | – | May 7, 2026 |
| Carolyn Ng | Director | 0 | – | May 7, 2026 |
| Jon Winkelried | – | – | – | May 13, 2026 |
| Tpg Gp A, Llc | – | – | – | May 13, 2026 |
| James G. Coulter | – | 3,690,146 | 7.68% | May 13, 2026 |
| Sr One Capital Management, Llc | 10% owner | – | – | May 11, 2026 |
| Simeon George | 10% owner | 2,376,914 | 4.95% | May 11, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| James G. Coulter – | May 11, 2026 | Buy | +1,388,889 | $18.00 | $25.00M | 3,690,146 |
| James G. Coulter – | May 11, 2026 | Conversion | +1,880,497 | – | – | 2,301,257 |
| James G. Coulter – | May 11, 2026 | Other | −2,351 | $18.00 | $42.32K | 420,760 |
| James G. Coulter – | May 11, 2026 | Other | +423,111 | – | – | 423,111 |
| Simeon George 10% owner | May 11, 2026 | Conversion | +139,366 | – | – | 613,414 |
| Simeon George 10% owner | May 11, 2026 | Sale | −438 | $18.00 | $7.88K | 814,851 |
| Simeon George 10% owner | May 11, 2026 | Option exercise | +78,656 | – | – | 815,289 |
| Simeon George 10% owner | May 11, 2026 | Conversion | +273,527 | – | – | 736,633 |
| Simeon George 10% owner | May 11, 2026 | Conversion | +463,106 | – | – | 463,106 |
| Simeon George 10% owner | May 11, 2026 | Buy | +133,333 | $18.00 | $2.40M | 574,314 |
| Simeon George 10% owner | May 11, 2026 | Sale | −277 | $18.00 | $4.99K | 440,981 |
| Simeon George 10% owner | May 11, 2026 | Option exercise | +49,850 | – | – | 441,258 |
| Simeon George 10% owner | May 11, 2026 | Conversion | +166,168 | – | – | 391,408 |
| Simeon George 10% owner | May 11, 2026 | Conversion | +20,582 | – | – | 225,240 |
| Simeon George 10% owner | May 11, 2026 | Conversion | +204,658 | – | – | 204,658 |
| Simeon George 10% owner | May 11, 2026 | Conversion | +255,823 | – | – | 374,335 |
| Simeon George 10% owner | May 11, 2026 | Conversion | +118,512 | – | – | 118,512 |
| Simeon George 10% owner | May 11, 2026 | Buy | +222,222 | $18.00 | $4.00M | 1,831,383 |
| Simeon George 10% owner | May 11, 2026 | Sale | −1,065 | $18.00 | $19.17K | 1,609,161 |
| Simeon George 10% owner | May 11, 2026 | Option exercise | +191,541 | – | – | 1,610,226 |
| Simeon George 10% owner | May 11, 2026 | Conversion | +683,817 | – | – | 1,418,685 |
| Simeon George 10% owner | May 11, 2026 | Conversion | +61,762 | – | – | 734,868 |
| Simeon George 10% owner | May 11, 2026 | Conversion | +59,692 | – | – | 673,106 |
| Simeon George 10% owner | May 11, 2026 | Buy | +200,000 | $18.00 | $3.60M | 1,014,851 |
| Simeon George 10% owner | May 11, 2026 | Conversion | +474,048 | – | – | 474,048 |
| Anthony W. Opipari See Remarks | May 11, 2026 | Option exercise | +541 | – | – | 7,506 |
| Anthony W. Opipari See Remarks | May 11, 2026 | Tax withholding | −4 | $18.00 | $72 | 7,502 |
| Anthony W. Opipari See Remarks | May 11, 2026 | Conversion | +6,965 | – | – | 6,965 |
| Jeffrey M. Leiden Director | May 11, 2026 | Conversion | +28,698 | – | – | 28,698 |
| Jeffrey M. Leiden Director | May 11, 2026 | Tax withholding | −17 | $18.00 | $306 | 31,644 |
| Jeffrey M. Leiden Director | May 11, 2026 | Option exercise | +2,963 | – | – | 31,661 |
| Gary D. Glick See Remarks, Director | May 11, 2026 | Conversion | +27,386 | – | – | 415,973 |
| Nan (LN) Li Director | May 11, 2026 | Buy | +1,111,111 | $18.00 | $20.00M | 3,333,516 |
| Nan (LN) Li Director | May 11, 2026 | Conversion | +1,709,543 | – | – | 2,222,405 |
| Shelley Chu Director | May 11, 2026 | Buy | +11,111 | $18.00 | $200.00K | 11,111 |
| Dimension Capital II, L.P. Director | May 8, 2026 | Buy | +1,111,111 | $18.00 | $20.00M | 3,333,516 |
| Dimension Capital II, L.P. Director | May 8, 2026 | Conversion | +1,709,543 | – | – | 2,222,405 |
| Jeffrey M. Leiden Director | May 8, 2026 | Buy | +5,000 | $20.00 | $100.00K | 270,198 |
| Jason Haas Chief Financial Officer | May 8, 2026 | Buy | +1,000 | $20.00 | $20.00K | 62,908 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 6 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Odyssey Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 33,405 shares on Sep 21, 2026 over the last 90 days.
See a number that looks wrong?